Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

NCT03233204 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03233204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03233204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2017
Completion date
June 30, 2024
Enrollment
6 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, ann arbor stage iii childhood non-hodgkin lymphoma, ann arbor stage iv childhood non-hodgkin lymphoma, low grade glioma, malignant glioma, recurrent childhood central nervous system neoplasm, recurrent childhood ependymoma, recurrent childhood malignant germ cell tumor, recurrent childhood non-hodgkin lymphoma, recurrent childhood rhabdomyosarcoma, recurrent childhood soft tissue sarcoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent glioma, recurrent hepatoblastoma, recurrent langerhans cell histiocytosis, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent osteosarcoma, refractory childhood malignant germ cell tumor, refractory ependymoma, refractory ewing sarcoma/peripheral primitive neuroectodermal tumor, refractory glioma, refractory hepatoblastoma, refractory langerhans cell histiocytosis, refractory malignant glioma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory primary central nervous system neoplasm, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, rhabdoid tumor, wilms tumor